Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Simcere Pharmaceutical Group Limited
先聲藥業集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT

THE CLINICAL TRIAL APPROVAL FOR SIM0725 (CD122) ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Simcere Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that SIM0725, an anti-CD122 antibody independently developed by the Group, has received the Clinical Trial Approval issued by the National Medical Products Administration (國家藥品監督管理局) of China and is proposed to be used for the treatment of autoimmune diseases.

ABOUT SIM0725

SIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta chain (CD122). SIM0725 can block interleukin-2 (IL-2) and interleukin-15 (IL-15)-mediated signalling, thereby suppressing the responses of relevant effector T cells and memory T cells, and is expected to influence autoimmune responses associated with disease persistence and relapse by interfering with the survival and maintenance of IL-15-dependent pathogenic tissue-resident memory T cells. Preclinical studies showed that, in humanised mouse pharmacodynamic models, SIM0725 demonstrated stronger pharmacodynamic activity than the comparator molecules tested, with less impact on the number and proliferation of regulatory T cells, suggesting its differentiated

immunomodulatory potential. In addition, SIM0725 exhibited markedly prolonged pharmacokinetic and pharmacodynamic effects in cynomolgus monkeys, supporting the potential for less frequent dosing in the clinical setting. SIM0725 has broad application prospects in autoimmune diseases such as vitiligo, alopecia areata, coeliac disease and eosinophilic oesophagitis, and has the potential to be developed as a "pipeline in a product".

ABOUT THE GROUP

The Company is an innovation and R&D-driven pharmaceutical company and the Group has established a "State Key Laboratory of Neurology and Oncology Drug Development". The Group focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of "for patients, for life". Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, November 10, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. TANG Renhong as the non-executive Director; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.